ライフサイエンスコーパス: accessory pathway

1 seemed to be driven by a right anteroseptal accessory pathway.

2 ciprocating tachycardia (ORT) using a septal accessory pathway.

3 shing atypical AVNRT from ORT using a septal accessory pathway.

4 ay in the concealed, retrogradely conducting accessory pathway.

5 e to slowing of retrograde conduction in the accessory pathway.

6 agnostic of the presence of a left free wall accessory pathway.

7 squerading as tachycardia using a left-sided accessory pathway.

8 on, masquerading as tachycardia using a left accessory pathway.

9 ial ablation fails in the elimination of the accessory pathway.

10 patients undergoing catheter ablation of an accessory pathway.

11 erwent ablation for epicardial posteroseptal accessory pathways.

12 lopment of the cardiac conduction system and accessory pathways.

13 in 13 patients, including 4 with left-sided accessory pathways.

14 to an age-matched cohort with nondecremental accessory pathways.

15 patients, 9%); 6) epicardial location of the accessory pathway (5 patients, 8%); 7) recurrent atrial

16 apping error due to an oblique course of the accessory pathway (7 patients, 11%); 4) failure to recog

17 tes (87.6% versus 90.6%, P=0.11), for single accessory pathways (94.5% versus 91.5%, P=0.4), or for t

18 tiate atypical AVNRT from ORT using a septal accessory pathway, a definitive diagnosis is occasionall

19 ), and the percentage of patients undergoing accessory pathway ablation was greatest in the <60-year-

20 males) referred for percutaneous epicardial accessory pathway ablation.

21 ocedure may facilitate successful outcome of accessory pathway ablation.

22 y be beneficial, along with consideration of accessory-pathway ablation in those deemed to be at high

23 ith ablations for (1) anterior and midseptal accessory pathways and atrioventricular nodal reentry an

24 ocardium of mice can produce fully penetrant accessory pathways and ventricular preexcitation.

25 -12 secretion is dependent on the CD40L/CD40 accessory pathway, and, utilizing a Th cell-free system,

26 ventricular preexcitation involving multiple accessory pathways, and conduction system disease, inclu

27 f the atrial or ventricular insertion of the accessory pathway; and 7) searching within the coronary

28 , 11 years), and was associated with a short accessory pathway antegrade refractory period (P<0.001)

29 The role of adenosine in uncovering dormant accessory pathway (AP) conduction after AP ablation is u

30 adequacy of electrophysiological mapping of accessory pathway (AP) locations in 15 patients at 27 ta

31 CSAP was defined by accessory pathway (AP) potential or earliest activation

32 Adverse accessory pathway (AP) properties were defined according

33 patients had a right- and 4 had a left-sided accessory pathway (AP), 4 patients had inappropriate sin

34 ular nodal reentrant tachycardia (AVNRT), an accessory pathway (AP), or the atrioventricular junction

35 Transcatheter ablation of accessory pathway (AP)-mediated tachycardia is routinely

36 nosis between tachycardia mediated by septal accessory pathways (AP) and atypical atrioventricular no

37 de on the conduction system in patients with accessory pathways (AP).

38 1%); 4) failure to recognize a posteroseptal accessory pathway as being left-sided instead of right-s

39 Radiofrequency ablation of accessory pathways at times requires a lengthy procedure

40 on alone eliminated epicardial posteroseptal accessory pathway conduction in 17 of 26 (65%) patients

41 For AVRT, a sustained effect on accessory pathway conduction occurred -3.3 +/- 4.9 s aft

42 d that some posteroseptal and left posterior accessory pathways (CSAPs) result from connections betwe

43 terograde effective refractory period of the accessory pathway cutoff of 240 milliseconds.

44 T) in patients with decrementally conducting accessory pathway (DAP) is a helpful maneuver to prove p

45 Although retrograde decremental accessory pathways (DAPs) are thought to typically prese

46 omatic and asymptomatic children had similar accessory pathway effective refractory periods and supra

47 ltivariable analysis demonstrated that short accessory-pathway effective refractory period (P<0.001)

48 up with malignant arrhythmias showed shorter accessory-pathway effective refractory period (P<0.001)

49 These results suggest that GC inhibit accessory pathways for IL-2 production via CD28 by predo

50 syndrome to help elucidate the mechanisms of accessory pathway formation.

51 for NIK as a histone H3 modifier, through an accessory pathway from NIK to IKKalpha, that could play

52 e of the 44 patients with ORT using a septal accessory pathway had an S-A-VA interval >85 ms and PPI-

53 rd of heart failure for a right anteroseptal accessory pathway (HR, 5.88; 95% CI, 2.63-13.1).

54 xtrastimuli showed evidence of a decremental accessory pathway in 3 of the 4 cases.

55 The accessory pathway in the 65 patients in this study was l

56 y in 4 and, after successful ablation of the accessory pathway, in 7.

57 For patients with midseptal and parahissian accessory pathways, in whom the risk of producing inadve

58 ntricular dissociation ruling out extranodal accessory pathways, including atriofascicular pathways.

59 procainamide-sensitive, adenosine-resistant accessory pathways induced in postnatal life that may ra

60 t-sided (4 patients, 6%); 5) other errors in accessory pathway localization (6 patients, 9%); 6) epic

61 spect of catheter manipulation and errors in accessory pathway localization.

62 Subgroup analysis on accessory pathway location revealed a higher adjusted ha

63 of multiple pathways (20% vs 16% vs 16%) or accessory pathway location.

64 or failed attempt at catheter ablation of an accessory pathway may be due to a variety of reasons, th

65 reentry tachycardia (n = 13), reentry via an accessory pathway (n = 4) or via twin atrioventricular n

66 Neither success for infants with a single accessory pathway nor complications for the entire infan

67 tory Ca(2+) is not bound, which generates an accessory pathway of activation; and 5), there is incomp

68 ]/with [n=3] a bystander nodofascicular [NF] accessory pathway, orthodromic reciprocating tachycardia

69 (P<0.001) and more often exhibited multiple accessory pathways (P<0.001), and atrioventricular reent

70 [50%]), or terminated (5/8 [63%]) SVT in all accessory pathway patients.

71 ing within the coronary sinus for a presumed accessory pathway potential.

72 ay proliferative responses, whereas CD2/CD28 accessory pathway proliferative responses are relatively

73 Ablation of the accessory pathway provides definitive treatment for PJRT

74 have been reported with atrial tachycardias, accessory pathway reciprocating tachycardias, atrioventr

75 underlying the development and conduction of accessory pathways remain unknown.

76 Ablation of epicardial posteroseptal accessory pathways requires ablation within the coronary

77 drome, this enabled understanding of complex accessory pathways resistant to previous ablation.

78 stimulatory signals through the LFA-1/ICAM-1 accessory pathway that are sufficient to induce early Th

79 t manifestation in 80% of the children of an accessory pathway that can precipitate a life-threatenin

80 ion (2 patients, 3%); 9) unusual right-sided accessory pathway that inserted in the anterior right ve

81 White syndrome, is caused by the presence of accessory pathways that can rapidly conduct electrical i

82 patients undergoing catheter ablation of an accessory pathway, the mean ablation time +/- SD was 68

83 VNRT and 44 patients with ORT using a septal accessory pathway, the right ventricle was paced at a cy

84 Epicardial mapping and ablation of accessory pathways through a subxiphoid approach can be

85 ogramming, to allow robust conduction across accessory pathway tissue.

86 vely localize ventricular insertion sites of accessory pathways to guide ablation and evaluate its ou

87 n=4] or NF [NF reentrant tachycardia; n=2]) accessory pathway underwent electrophysiological study.

88 A distinct AV accessory pathway was confirmed by electrical and pharma

89 Ablation of the accessory pathway was successful in 19 of 21 patients.

90 Bystander accessory pathways were only identified by His-refractor

91 tched control population with nondecremental accessory pathways who underwent electrophysiology study